Back to Search
Start Over
Validation of neuron-specific enolase in cardiac arrest patients with limited withdrawal of life-sustaining therapy
- Source :
- Heliyon, Vol 10, Iss 14, Pp e34618- (2024)
- Publication Year :
- 2024
- Publisher :
- Elsevier, 2024.
-
Abstract
- Aim: We validated the prognostic performance of neuron-specific enolase (NSE) according to the recommended values in cardiac arrest (CA) survivors. Methods: We analyzed the data of adult CA survivors who underwent targeted temperature management between January 2014 and December 2020. We measured the NSE level 48 h and 72 h after CA. We performed receiver operating characteristics (ROC) and used the reference value (17 μg/L) and the guidelines-suggested value (60 μg/L) as thresholds. The primary outcome was 6-month neurological outcomes with Cerebral Performance Category (CPC), dichotomized into good (CPC 1 or 2) or poor (CPC 3–5). Results: Of the 513 included patients, 346 (67.4 %) patients had poor neurological outcomes. The area under ROC (AUC) of NSE at 48 h was 0.887 (95 % confidence intervals [CIs], 0.851–0.909) with the Youden index of 35.6 μg/L. A false positive rate (FPR) of
- Subjects :
- Science (General)
Q1-390
Social sciences (General)
H1-99
Subjects
Details
- Language :
- English
- ISSN :
- 24058440
- Volume :
- 10
- Issue :
- 14
- Database :
- Directory of Open Access Journals
- Journal :
- Heliyon
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.423d172bd1436b95a423309d07743f
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.heliyon.2024.e34618